CLAIMS

1. The use of ulipristal, or any active metabolite thereof, in the manufacture of a medicament for the treatment of pain associated with dislocation of the endometrium, wherein said ulipristal, or said active metabolite thereof, is to be administered at a daily dosage at a therapeutically effective amount of 5 to 12 mg.

2. The use, according to claim 1, wherein the dislocation of basal endometrium results in adenomyosis or in endometriosis.

3. The use, according to claim 1 or 2, wherein the pain is selected from the group comprising chronic pelvic pain, pain before and during periods, pain with intercourse, low back pain, painful bowel movements (especially during menstruation) and painful urination during menstruation.

4. The use, according to any one of the preceding claims, wherein the patient is to be administered with a tablet comprising ulipristal or any active metabolite thereof.

5. The use, according to any one of the preceding claims, wherein the daily dosage of ulipristal, or any active metabolite thereof, is about 5 mg.

6. The use, according to any one of claims 1 - 4, wherein the daily dosage of ulipristal, or any active metabolite thereof, is about 10 mg.

7 The use, according to any one of the preceding claims, wherein said ulipristal metabolite is selected from the group comprising CDB-3877, CDB-3963, CDB-3236, and CDB-4183.

8. The use, according to any one of the preceding claims, wherein ulipristal or an active metabolite thereof is to be administered for a period of 1 to up to 120 days.

9. The use of ulipristal, or any active metabolite thereof, in the manufacture of a medicament for ~~in~~ reducing or stopping menstrual bleeding associated with endometriosis/adenomyosis wherein said ulipristal, or said active metabolite thereof, is to be administered a daily dosage of 5 to 12 mg.

10. The use of ulipristal, or any active metabolite thereof, in the manufacture of a medicament for preventing or treating anemia arising from heavy menstrual bleeding wherein said

ulipristal, or said active metabolite thereof, is to be administered a daily dosage of 5 to 12 mg.

11. The use of ulipristal, or any active metabolite thereof, in the manufacture of a medicament for reducing uterine volume in a patient afflicted with dislocation of the endometrium, comprising the administration to said patient in need thereof, a daily dosage of 5 to 12 mg of ulipristal, or any active metabolite thereof.

12. A kit for treating and/or preventing pain associated with dislocation of the endometrium, comprising ulipristal, or any active metabolite thereof to be administered at a daily dosage at a therapeutically effective amount of 5 to 12 mg, with reagents and/or instructions for use.

CLAIMS

1. The use of ulipristal, or any active metabolite thereof, in the manufacture of a medicament for the treatment of pain associated with dislocation of the endometrium, wherein said ulipristal, or said active metabolite thereof, is to be administered at a daily dosage at a therapeutically effective amount of 5 to 12 mg.

2. The use, according to claim 1, wherein the dislocation of basal endometrium results in adenomyosis or in endometriosis.

3. The use, according to claim 1 or 2, wherein the pain is selected from the group comprising chronic pelvic pain, pain before and during periods, pain with intercourse, low back pain, painful bowel movements (especially during menstruation) and painful urination during menstruation.

4. The use, according to any one of the preceding claims, wherein the patient is to be administered with a tablet comprising ulipristal or any active metabolite thereof.

5. The use, according to any one of the preceding claims, wherein the daily dosage of ulipristal, or any active metabolite thereof, is about 5 mg.

6. The use, according to any one of claims 1 - 4, wherein the daily dosage of ulipristal, or any active metabolite thereof, is about 10 mg.

7 The use, according to any one of the preceding claims, wherein said ulipristal metabolite is selected from the group comprising CDB-3877, CDB-3963, CDB-3236, and CDB-4183.

8. The use, according to any one of the preceding claims, wherein ulipristal or an active metabolite thereof is to be administered for a period of 1 to up to 120 days.

9. The use of ulipristal, or any active metabolite thereof, in the manufacture of a medicament for ~~in~~ reducing or stopping menstrual bleeding associated with endometriosis/adenomyosis wherein said ulipristal, or said active metabolite thereof, is to be administered a daily dosage of 5 to 12 mg.

10. The use of ulipristal, or any active metabolite thereof, in the manufacture of a medicament for preventing or treating anemia arising from heavy menstrual bleeding wherein said

ulipristal, or said active metabolite thereof, is to be administered a daily dosage of 5 to 12 mg.

11. The use of ulipristal, or any active metabolite thereof, in the manufacture of a medicament for reducing uterine volume in a patient afflicted with dislocation of the endometrium, comprising the administration to said patient in need thereof, a daily dosage of 5 to 12 mg of ulipristal, or any active metabolite thereof.